One Kendall Square
4th Floor Suite B14402 Building 1400 West
Cambridge, MA 02139
United States
617 863 5500
https://www.invivotherapeutics.com
Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 6
Nom | Titre | Payer | Exercé | Année de naissance |
---|---|---|---|---|
Dr. Richard M. Toselli M.D. | President, CEO, Chief Medical Officer & Director | 825,2k | S.O. | 1958 |
Mr. Richard C. Christopher | CFO & Treasurer | 537,82k | S.O. | 1970 |
Ms. Heather M. Hamel J.D. | Chief Legal Officer & General Counsel | 446,96k | S.O. | 1990 |
Dr. Robert S. Langer Jr., Ph.D., ScD | Co-Founder & Member of Scientific Advisory Board | S.O. | S.O. | 1949 |
Dr. Joseph Philip Vacanti M.D. | Co-Founder | S.O. | S.O. | 1949 |
InVivo Therapeutics Holdings Corp. operates as a research and clinical-stage biomaterials and biotechnology company in the United States. The company engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI). It is developing a Neuro-Spinal Scaffold implant comprise of biocompatible and bioresorbable polymers, which includes Poly lactic-co-glycolic acid, a polymer which is widely used in resorbable sutures and provides the biocompatible support for Neuro-Spinal Scaffold implant; and Poly-L-Lysine, a positively charged polymer used to coat surfaces to promote cellular attachment. The company was incorporated in 2003 and is headquartered in Cambridge, Massachusetts.
L’ISS Governance QualityScore de InVivo Therapeutics Holdings Co en date du S.O. est S.O.. Les scores principaux sont Audit : S.O.; Société : S.O.; Droits des actionnaires : S.O.; Compensation : S.O..